TRex Bio's $116.7 Million IPO Finds a Floor at $14
Lilly's indicated interest and five bookrunners helped TRex Bio preserve its full share count, but low-end pricing and a flat debut leave the next rerating to clinical data.
SOUTH SAN FRANCISCO, Calif., October 10, 2026
TRex Bio reached the public market with enough institutional sponsorship to sell the full base deal, but without the scarcity premium that biotech issuers covet. The tissue-immunology developer sold 8,333,334 primary shares at $14 each, the bottom of its marketed $14 to $16 range, for $116.7 million of gross proceeds. The stock opened Friday at $13.50, traded as high as $15.50 and finished at the $14 issue price, according to IPO Scoop's account of the debut.
That sequence matters more than a simple flat-return label. TRex Bio did not cut the 8.33 million-share base deal, and all shares came from the company. Yet the book cleared only at the range floor and the first trade arrived below issue. IPOGrid reads this as a price-sensitive financing that got done at useful scale, with buyers willing to fund the clinical plan but unwilling to award an immediate premium. At $14, the offering valued the company at roughly $384 million on the basic post-IPO share count reported by IPO Scoop.
The visible support came from Eli Lilly. In the preliminary prospectus, Lilly indicated interest in buying enough IPO shares so that its existing and new holdings together would reach no more than 19.9% of post-offering shares. That was an indication, not a binding order, and the final allocation was not disclosed. Still, Lilly is more than a financial name on the cover: it is TRex Bio's collaboration partner on TRB-051, a program the company says is advancing into a Phase 2a lupus study. The strategic overlap gives the indicated demand more informational weight than an unaffiliated crossover order, even if it does not validate either of TRex Bio's wholly owned lead assets.
A full-sized deal, with restrained aftermarket enthusiasm
The underwriting group also gave the transaction reach. J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow acted as bookrunners, and the company granted a 30-day option for another 1.25 million shares. TRex Bio said trading would begin October 9 and the offering is expected to close October 13, subject to customary conditions, in its pricing announcement. The issuer's final prospectus confirms the $14 price and the all-primary deal.
The reviewer’s concern is that strong names around the transaction did not produce strong price discovery. The stock recovered from its discounted opening, which suggests support around the offer price, but it surrendered the intraday premium by the close. For a pre-revenue biotech, that leaves the public case anchored to execution rather than deal momentum.
TRex Bio had $90.9 million of cash and marketable securities at June 30, while its loss before income taxes widened to $29.3 million in the first half of 2026 from $17.7 million a year earlier, according to the final prospectus. Research and development expense rose to $26.0 million from $15.0 million over the same periods. The historical revenue line is also lumpy: collaboration revenue was $39.1 million in 2024 and zero in 2025. Our interpretation is that investors should underwrite TRex Bio as a cash-consuming clinical platform, not extrapolate the 2024 collaboration payment into an operating revenue base.
Mid-2027 is the next major test
Proceeds are intended mainly to advance the wholly owned TRB-061 and TRB-071 programs, with the balance available for working capital and general corporate purposes. TRB-061 is a TNFR2 agonist designed to activate and expand regulatory T cells in inflamed tissue. In August, TRex Bio reported that the Phase 1a study in healthy volunteers showed consistent pharmacokinetics and reproducible Treg activation and expansion, with no treatment-related serious adverse events or dose-limiting toxicities. Those were early safety and biomarker results, not efficacy data. The ongoing Phase 1b study in moderate-to-severe atopic dermatitis is expected to produce topline data in mid-2027, according to the company's Phase 1a update.
TRB-071, a CD30 agonist aimed initially at inflammatory bowel disease, remains in IND-enabling work. The company's pipeline page identifies it as the second wholly owned program and describes Lilly-partnered TRB-051 separately. That distinction is important: Lilly's participation supports the platform relationship, while public shareholders are supplying capital principally for programs whose clinical value remains TRex Bio's responsibility to establish.
The IPO therefore buys time and preserves optionality, but it does not settle the scientific argument. The intact share count, Lilly interest and broad bank group are constructive. The range-floor price, below-issue opening and flat close show the limit of that support. TRex Bio now has a public currency and more than $100 million of gross new capital. The next meaningful premium will have to come from patient data.